• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

消化道肿瘤中mA调控因子的修饰模式及代谢特征

Modification patterns and metabolic characteristics of mA regulators in digestive tract tumors.

作者信息

He Bing, Hu Yiyang, Chen Hui, Xie Xia, Gong Chunli, Li Zhibin, Chen Yang, Xiao Yufeng, Yang Shiming

机构信息

Department of Gastroenterology, Xinqiao Hospital, Army Military Medical University, Chongqing, 400037, China.

出版信息

Heliyon. 2024 Jan 14;10(2):e24235. doi: 10.1016/j.heliyon.2024.e24235. eCollection 2024 Jan 30.

DOI:10.1016/j.heliyon.2024.e24235
PMID:38298699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10828661/
Abstract

M6A is essential for tumor occurrence and progression. The expression patterns of m6A regulators differ in various kinds of tumors. Transcriptomic expression statistics together with clinical data from a database were analyzed to distinguish patients with digestive tract tumors. Based on the expression patterns of diverse m6A regulators, patients were divided into several clusters. Survival analysis suggested significant differences in patient prognosis among the m6A clusters. The results showed overlapping of m6A expression patterns with energy metabolism and nucleotide metabolism. Functional analyses imply that m6A modifications in tumor cells probably drive metabolic reprogramming to sustain rapid proliferation of cancer cells. Our analysis highlights the m6A risk characterizes various kinds of metabolic features and predicts chemotherapy sensitivity in digestive tract tumors, providing evidence for m6A regulators as markers to predict patient outcomes.

摘要

m6A对于肿瘤的发生和进展至关重要。m6A调控因子的表达模式在各种肿瘤中有所不同。分析了来自数据库的转录组表达统计数据以及临床数据，以区分消化道肿瘤患者。根据不同m6A调控因子的表达模式，将患者分为几个簇。生存分析表明，m6A簇之间患者预后存在显著差异。结果显示m6A表达模式与能量代谢和核苷酸代谢存在重叠。功能分析表明，肿瘤细胞中的m6A修饰可能驱动代谢重编程以维持癌细胞的快速增殖。我们的分析突出了m6A风险表征各种代谢特征并预测消化道肿瘤化疗敏感性，为将m6A调控因子作为预测患者预后的标志物提供了证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/cd690a0cae69/mmcfigs8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/1dae84619ca8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/ae66ee1a145b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/4a667f160081/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/2d965ba58423/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/feff3d771ce6/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/386c90ba67c3/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/ed1b5c86452f/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/e99ab597e625/mmcfigs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/34008332bfda/mmcfigs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/8ddeb49008dc/mmcfigs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/19c1396019fe/mmcfigs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/e88cd09c0d5b/mmcfigs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/49b09a2b3413/mmcfigs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/32f0d4d4522f/mmcfigs7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/cd690a0cae69/mmcfigs8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/1dae84619ca8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/ae66ee1a145b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/4a667f160081/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/2d965ba58423/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/feff3d771ce6/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/386c90ba67c3/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/ed1b5c86452f/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/e99ab597e625/mmcfigs1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/34008332bfda/mmcfigs2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/8ddeb49008dc/mmcfigs3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/19c1396019fe/mmcfigs4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/e88cd09c0d5b/mmcfigs5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/49b09a2b3413/mmcfigs6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/32f0d4d4522f/mmcfigs7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af88/10828661/cd690a0cae69/mmcfigs8.jpg

相似文献

1
Modification patterns and metabolic characteristics of mA regulators in digestive tract tumors.消化道肿瘤中mA调控因子的修饰模式及代谢特征
Heliyon. 2024 Jan 14;10(2):e24235. doi: 10.1016/j.heliyon.2024.e24235. eCollection 2024 Jan 30.
2
Effects of N6-methyladenosine modification on metabolic reprogramming in digestive tract tumors.N6-甲基腺嘌呤修饰对消化道肿瘤代谢重编程的影响。
Heliyon. 2024 Jan 11;10(2):e24414. doi: 10.1016/j.heliyon.2024.e24414. eCollection 2024 Jan 30.
3
Systematic analysis of molecular characterization and clinical relevance of m6A regulators in digestive system pan-cancers.系统分析 m6A 调节剂在消化系统癌症中的分子特征和临床相关性。
Exp Biol Med (Maywood). 2021 Sep;246(18):2007-2018. doi: 10.1177/15353702211019681. Epub 2021 Jun 8.
4
Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation.基于 m6A RNA 甲基化调控因子的甲状腺癌风险预测模型：整合生物信息学分析和组织学验证。
Aging (Albany NY). 2023 Feb 15;15(3):846-865. doi: 10.18632/aging.204525.
5
Identification of clinical prognostic features of esophageal cancer based on m6A regulators.基于 m6A 调节因子鉴定食管癌的临床预后特征。
Front Immunol. 2022 Sep 8;13:950365. doi: 10.3389/fimmu.2022.950365. eCollection 2022.
6
Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.使用m6A RNA甲基化调节因子构建前列腺癌风险预测模型：综合生物信息学分析与组织学验证
Cancer Cell Int. 2022 Jan 19;22(1):33. doi: 10.1186/s12935-021-02438-1.
7
The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.m6A RNA 甲基化修饰在宫颈癌预后和肿瘤微环境免疫浸润中的意义。
Medicine (Baltimore). 2022 Jul 1;101(26):e29818. doi: 10.1097/MD.0000000000029818.
8
The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.m6A 甲基化图谱将肝细胞癌分为具有不同代谢特征的 3 个亚型。
Cancer Biol Med. 2020 Nov 15;17(4):937-952. doi: 10.20892/j.issn.2095-3941.2020.0402. Epub 2020 Dec 15.
9
Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.非小细胞肺癌中 m6A RNA 甲基化调控因子与肿瘤免疫微环境的综合分析
Dis Markers. 2022 Feb 9;2022:2989200. doi: 10.1155/2022/2989200. eCollection 2022.
10
Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.全面描述 m6A 甲基化及其对肝细胞癌预后、基因组不稳定性和肿瘤微环境的影响。
BMC Med Genomics. 2022 Mar 8;15(1):53. doi: 10.1186/s12920-022-01207-x.

引用本文的文献

1
Research trends of protein palmitoylation in cancer from 2004 to 2024: a bibliometric and visualization analysis.2004年至2024年癌症中蛋白质棕榈酰化的研究趋势：文献计量与可视化分析
Front Oncol. 2025 Jun 23;15:1571870. doi: 10.3389/fonc.2025.1571870. eCollection 2025.

本文引用的文献

1
Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.用小干扰RNA靶向N6-甲基腺苷阅读器YTHDF1，通过抑制EZH2-IL-6轴增强非酒精性脂肪性肝炎相关肝细胞癌的抗肿瘤免疫力。
J Hepatol. 2023 Nov;79(5):1185-1200. doi: 10.1016/j.jhep.2023.06.021. Epub 2023 Jul 17.
2
FABP5 suppresses colorectal cancer progression via mTOR-mediated autophagy by decreasing FASN expression.FABP5 通过降低 FASN 表达，经 mTOR 介导的自噬来抑制结直肠癌细胞的进展。
Int J Biol Sci. 2023 Jun 12;19(10):3115-3127. doi: 10.7150/ijbs.85285. eCollection 2023.
3
A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer.
联合计算和功能方法确定 IGF2BP2 是广泛的结直肠癌临床前模型中化学耐药性的驱动因素。
Mol Cancer. 2023 May 30;22(1):89. doi: 10.1186/s12943-023-01787-x.
4
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy.YTHDF2 抑制增强放疗抗肿瘤疗效。
Cancer Cell. 2023 Jul 10;41(7):1294-1308.e8. doi: 10.1016/j.ccell.2023.04.019. Epub 2023 May 25.
5
RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8 T cell infiltration in colorectal cancer.RNA去甲基化酶ALKBH5通过抑制增殖和侵袭以及促进CD8 T细胞浸润来抑制结直肠癌的肿瘤发生。
Transl Oncol. 2023 Aug;34:101683. doi: 10.1016/j.tranon.2023.101683. Epub 2023 May 22.
6
ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.ALKBH5 通过靶向 AXIN2 促进结直肠癌并促进免疫治疗，从而发挥免疫抑制作用。
Gastroenterology. 2023 Aug;165(2):445-462. doi: 10.1053/j.gastro.2023.04.032. Epub 2023 May 9.
7
Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.二甲双胍通过抑制 METTL3 介导的 THRAP3、RBM25 和 USP4 的 m6A 甲基化来抑制多发性骨髓瘤细胞增殖并促进细胞凋亡。
Cell Cycle. 2023 Apr;22(8):986-1004. doi: 10.1080/15384101.2023.2170521. Epub 2023 Feb 10.
8
Updated epidemiology of gastrointestinal cancers in East Asia.东亚地区胃肠道癌症的最新流行病学情况。
Nat Rev Gastroenterol Hepatol. 2023 May;20(5):271-287. doi: 10.1038/s41575-022-00726-3. Epub 2023 Jan 11.
9
The mA reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia.mA 阅读器 IGF2BP2 调节谷氨酰胺代谢，是急性髓系白血病的治疗靶点。
Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10. doi: 10.1016/j.ccell.2022.10.004. Epub 2022 Oct 27.
10
Augmentation of the RNA m6A reader signature is associated with poor survival by enhancing cell proliferation and EMT across cancer types.RNA m6A 读码器特征的增强通过增强细胞增殖和 EMT 促进多种癌症类型的不良预后。
Exp Mol Med. 2022 Jul;54(7):906-921. doi: 10.1038/s12276-022-00795-z. Epub 2022 Jul 6.